Paul Baas

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 6

Top Topics

Patients Undergoing

Prognostic Factors

Top Venues

Nature medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nature medicine 30 (6) (2024)
Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nature medicine (2024)
Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nature medicine 30 (6) (2024)
Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nature medicine 30 (6) (2024)
Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nature medicine (2024)
Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nature medicine 30 (6) (2024)